Previous 10 | Next 10 |
Image source: The Motley Fool. Syneos Health, Inc. (NASDAQ: SYNH) Q3 2020 Earnings Call Oct 29, 2020 , 8:00 a.m. ET Operator Continue reading For further details see: Syneos Health, Inc. (SYNH) Q3 2020 Earnings Call Transcript
Syneos Health (SYNH): Q3 Non-GAAP EPS of $1.04 beats by $0.14; GAAP EPS of $0.60 beats by $0.19.Revenue of $1.1B (-6.8% Y/Y) misses by $20M.Shares +3.17% PM.Press Release For further details see: Syneos Health EPS beats by $0.14, misses on revenue
Highlights Announced agreement to acquire Synteract, a mid-sized, full-service CRO focused on the fast growing emerging biopharma sector. GAAP revenue of $1,099.0 million for the three months ended September 30, 2020, representing a sequential increase of 8.4% compared to th...
MORRISVILLE, N.C., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and a CCO (Contract Commercial Organization), today announced an agreement to acqu...
Syneos Health (NASDAQ:SYNH) is scheduled to announce Q3 earnings results on Thursday, October 29th, before market open.The consensus EPS Estimate is $0.90 (+3.4% Y/Y) and the consensus Revenue Estimate is $1.12B (-5.1% Y/Y).Over the last 2 years, SYNH has beaten EPS estimates 88% of the time ...
ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. While mean reversion led to a September rally for value s...
MORRISVILLE, N.C., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Syneos Health (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today introduced Kinetic , a modern customer engagement capability that makes fully integrated omnichannel solutions accessible to biopha...
ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. While mean reversion led to a September rally for value s...
MORRISVILLE, N.C., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Syneos Health (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced the Company has been named to the Forbes 2020 list of World’s Be s t Employers , ranking highest among bio...
MORRISVILLE, N.C., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced that it was awarded the Society for Clinical Research Sites (SCRS) Ea g le Award , sweeping the CRO ca...
News, Short Squeeze, Breakout and More Instantly...
Mitsubishi Tanabe Pharma America Celebrates Eight-Year Anniversary in the U.S. PR Newswire JERSEY CITY, N.J. , April 29, 2024 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) is celebrating its eight-year anniversary of being established in th...
Mitsubishi Tanabe Pharma America to Showcase Breadth of Neurodegenerative Research at 2024 American Academy of Neurology Annual Meeting PR Newswire Presentations span Parkinson's disease and ALS clinical and real-world evidence Oral platform sessions will highlight r...
Mitsubishi Tanabe Pharma America Receives U.S. Food and Drug Administration Orphan Drug Exclusivity for RADICAVA ORS® (edaravone) PR Newswire Orphan Drug Exclusivity recognized for RADICAVA ORS based on major contribution to patient care JERSEY CITY, N.J. ...